By P. Roy. Saint Bonaventure University.
Often good hospitals have rape intervention programs aspirin 100 pills generic chronic pain syndrome treatment guidelines, and while these were developed to help women who were raped as adults or who have a history of child abuse discount aspirin 100pills with visa mtus chronic pain treatment guidelines, the good ones know to treat men as well, and often that help is free. At least they should be able to refer you to an appropriate place. There are also centers that treat abuse and incest in some cities. I have known boys who made it their business as they got older to find people in whom they could confide. If a boy or man feels too ashamed to talk to anyone about what happened, then it festers. I run groups for sexually abused men, and I am always amazed and gratified when they see that they are not alone and what a difference that makes to them. There are also some web sites now that have chat rooms and bulletin boards where sexually abused men or their partners can talk to one another anonymously, as you are doing here. My question is: How does one know which methodology to use in the resolution of this issue? For example, through further psychotherapy or via a medical approach, in the context of chronic depression and extensive abuse histories. I often see men in psychotherapy and refer them for medication consultations as an adjunct. If an antidepressant works, often the man begins to be able to behave differently in the world and then we have different, new things to talk about in the therapy. Gartner: It sounds like that sense of self had to come through covering up a terrible secret, so I wonder how solid it could be. Every case is different, of course, and I am not saying that every family in which abuse took place needs to dissolve. In fact, it is indeed very difficult to accuse, say a parent, of abuse and split the whole family if some believe you and some do not. I think that, in some way, the abuse has to be recognized, at least privately, for that sense of self to be solid. TFlynn: Do you really think that he would turn to another adult for help. Alcohol, drugs, gambling, overeating, overspending, and sexual compulsion are all things that men may turn to when they need to sooth the tremendous pain they feel. Often when men come to me it is because they finally realized that they were killing themselves through such self-abuse. Gartner: The conventional wisdom is that boys who are abused become men who are abusive, but the overwhelming majority do not. Although it is true that most abusers were themselves abused, they are the ones who turned to that hyper-masculine way of living, in which you act out your feelings rather than reflect on them. The fear that people will think you are an abuser, or the fear that you will become one, is another reason men are reluctant to speak of their histories. Gartner: Well, yes, that is what I was referring to -- these are the men who are living in pressure cookers. Also, we often imitate the behaviors we grew up with, so even if we do not become physically or sexually abusive, there may be a tendency either to become exploitative oneself or to be easily exploited by others if someone is "trained" to be a victim. There will be a conference in New York in October that is open to survivors as well as to professionals. I am the Program Chair and I know it will be very exciting. David: Are there any other seminars or retreats that you might recommend for our audience members to attend? Gartner: NOMSV is planning to offer retreats in the future -- we did do one in California two years ago. I would say check the web site from time to time to see whether one is scheduled.
There was a reproducible mutagenic response in the Ames assay in one strain of S generic 100 pills aspirin with mastercard treatment for dog gas pain. Positive results were obtained in both the in vitro mammalian cell gene mutation assay and the in vitro chromosomal aberration assay in human lymphocytes trusted aspirin 100pills pain treatment center sawgrass. Impairment of Fertility - Ziprasidone was shown to increase time to copulation in Sprague-Dawley rats in two fertility and early embryonic development studies at doses of 10 to 160 mg/kg/day (0. Fertility rate was reduced at 160 mg/kg/day (8 times the MRHD on a mg/m2 basis). There was no effect on fertility at 40 mg/kg/day (2 times the MRHD on a mg/m2 basis). The effect on fertility appeared to be in the female since fertility was not impaired when males given 160 mg/kg/day (8 times the MRHD on a mg/m2 basis) were mated with untreated females. In a 6-month study in male rats given 200 mg/kg/day (10 times the MRHD on a mg/m2 basis) there were no treatment-related findings observed in the testes. Pregnancy - Pregnancy Category C - In animal studies ziprasidone demonstrated developmental toxicity, including possible teratogenic effects at doses similar to human therapeutic doses. When ziprasidone was administered to pregnant rabbits during the period of organogenesis, an increased incidence of fetal structural abnormalities (ventricular septal defects and other cardiovascular malformations and kidney alterations) was observed at a dose of 30 mg/kg/day (3 times the MRHD of 200 mg/day on a mg/m2 basis). There was no evidence to suggest that these developmental effects were secondary to maternal toxicity. The developmental no-effect dose was 10 mg/kg/day (equivalent to the MRHD on a mg/m2 basis). In rats, embryofetal toxicity (decreased fetal weights, delayed skeletal ossification) was observed following administration of 10 to 160 mg/kg/day (0. Doses of 40 and 160 mg/kg/day (2 and 8 times the MRHD on a mg/m2 basis) were associated with maternal toxicity. The developmental no-effect dose was 5 mg/kg/day (0. There was an increase in the number of pups born dead and a decrease in postnatal survival through the first 4 days of lactation among the offspring of female rats treated during gestation and lactation with doses of 10 mg/kg/day (0. Offspring developmental delays and neurobehavioral functional impairment were observed at doses of 5 mg/kg/day (0. A no-effect level was not established for these effects. There are no adequate and well-controlled studies in pregnant women. Ziprasidone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Labor and Delivery - The effect of ziprasidone on labor and delivery in humans is unknown. Nursing Mothers - It is not known whether, and if so in what amount, ziprasidone or its metabolites are excreted in human milk. It is recommended that women receiving ziprasidone should not breast feed. Pediatric Use - The safety and effectiveness of ziprasidone in pediatric patients have not been established. Geriatric Use - Of the approximately 4500 patients treated with ziprasidone in clinical studies, 2. In general, there was no indication of any different tolerability of ziprasidone or for reduced clearance of ziprasidone in the elderly compared to younger adults. Nevertheless, the presence of multiple factors that might increase the pharmacodynamic response to ziprasidone, or cause poorer tolerance or orthostasis, should lead to consideration of a lower starting dose, slower titration, and careful monitoring during the initial dosing period for some elderly patients. The premarketing development program for oral ziprasidone included approximately 5700 patients and/or normal subjects exposed to one or more doses of ziprasidone. Of these 5700, over 4800 were patients who participated in multiple-dose effectiveness trials, and their experience corresponded to approximately 1831 patient-years. These patients include: (1) 4331 patients who participated in multiple-dose trials, predominantly in schizophrenia, representing approximately 1698 patient-years of exposure as of February 5, 2000; and (2) 472 patients who participated in bipolar mania trials representing approximately 133 patient-years of exposure. The conditions and duration of treatment with ziprasidone included open-label and double-blind studies, inpatient and outpatient studies, and short-term and longer-term exposure. The premarketing development program for intramuscular ziprasidone included 570 patients and/or normal subjects who received one or more injections of ziprasidone. Over 325 of these subjects participated in trials involving the administration of multiple doses.